Skip to main content

#156374

Anti-ABeta (Abeta) [6C3]

Cat. #156374

Anti-ABeta (Abeta) [6C3]

Cat. #: 156374

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: Amyloid-? Peptide

Class: Monoclonal

Application: IHC ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: University of Illinois Chicago

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-ABeta (Abeta) [6C3]
  • Alternate name: AÎ? or Abeta
  • Research fields: Apoptosis and autophagy;Cell biology;Developmental biology
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; WB
  • Description: Defects in APP are associated with the pathology of various types of Alzheimer's disease. Specially, the defective amyloid-beta-APP 40-42 peptides, which MOAB-2 targets exclusively, are major constituents of extracellular plaques and contribute cytotoxic neuronal death.
  • Immunogen: Human beta Amyloid. Recombinant oligomeric A?42. Epitope maps to residues 1-4 of human A?42 and A?40 (DAEF).
  • Recommended controls: IgG2b

Target Details

  • Target: Amyloid-? Peptide
  • Tissue cell line specificity: IgG2b
  • Target background: Defects in APP are associated with the pathology of various types of Alzheimer's disease. Specially, the defective amyloid-beta-APP 40-42 peptides, which MOAB-2 targets exclusively, are major constituents of extracellular plaques and contribute cytotoxic neuronal death.

Applications

  • Application: IHC ; WB

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Dry ice

References

  • 295587871
  • Fekete et al. 2019. Neuroscience. 405:35-46. PMID: 29522854.
  • Scaringi et al. 2012. Anticancer Res. 32(10):4213-23. PMID: 23060541.
  • Youmans et al. 2012. Mol Neurodegener. 7:8. PMID: 22423893.
  • Youmans et al. 2012. Mol Neurodegener. 7:8. PMID: 22423893.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.